ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity […]
ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the ‘Company’ / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.
ORLANDO, Fla., Aug. 27, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining […]
ORLANDO, Fla., Aug. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: MDIT / OTCBB:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.
